Angioimmunoblastic T cell lymphoma
Conditions
Interventions
Therapy group:AZA (Azacitidine) in combination with CHOP regimen
Sponsors
The First Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Newly diagnosed AITL by pathology. 2. Aged 18-70 years. 3. ECOG 0-2. 4. Obtain the informed consent signed by the patient or his family.
Exclusion criteria
Exclusion criteria: 1. Received systemic or local treatment including chemotherapy in the first three weeks. 2. Liver and kidney function: blood bilirubin > 2 mg/dl (35 umol/L), AST/ALT was more than 2 times of the upper limit of normal, serum creatinine was more than 177 umol/L, the creatinine clearance rate was less than 60 ml/min. 3. Normal heart function: EF <= 50%. 4. The expected survival time was less than 3 months. 5. Chronic or current active infectious diseases requiring systemic antibiotics, antifungal agents or antiviral therapy. 6. Other concurrent and uncontrollable factors are considered by the researchers to affect the medical status of patients participating in the study. Psychiatric patients or other patients who are known or suspected to be unable to fully comply with the study protocol. 7. People living with HIV.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Complete response rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival;Objective response rate;Progression free survival;Safety; | — |
Countries
China
Contacts
Public ContactJin Jie, Yu Wenjuan
The First Affiliated Hospital, College of Medicine, Zhejiang University
Outcome results
None listed